The cytokine TGF␤ plays a dual role in tumorigenesis. On one hand, TGF␤ inhibits the proliferation of normal epithelial, endothelial, and hematopoietic cells, thus being crucial for the homeostasis of these tissues (Massagué 1990; Roberts and Sporn 1993; Alexandrow and Moses 1995) . TGF␤ signaling is lost in some cancers by mutational inactivation of TGF␤ signal-transduction components. A substantial proportion of colorectal or pancreatic cancers harbor inactivating mutations in the genes encoding the TGF␤ type II receptor (T␤R-II) or its mediators, Smad2 and Smad4 (Markowitz et al. 1995; Eppert et al. 1996; Hahn et al. 1996; Heldin et al. 1997; Goggins et al. 1998; Massagué 1998; Grady et al. 1999 ). In the mouse, expression of a dominant-negative T␤R-II transgene in the pancreas, mammary gland, or skin causes abnormal growth of these tissues (Bö ttinger et al. 1996; Wang et al. 1997; Gorska et al. 1998) . Furthermore, Smad3 mutant mice (Zhu et al. 1998) or the combined loss of wild-type Smad4 and APC alleles in compound heterozygotes (Takaku et al. 1998) lead to formation of invasive intestinal tumors.
On the other hand, TGF␤ can exacerbate the malignant phenotype at later stages of tumorigenesis (Cui et al. 1996; Barrack 1997; Factor et al. 1997; Reiss and Barcellos-Hoff 1997) . TGF␤ is abundantly expressed in various tumors of epithelial origin (Derynck et al. 1985; Keski-Oja et al. 1987) in which it can suppress immune surveillance (Letterio and Roberts 1998) , foster tumor invasion (Cui et al. 1996) , and promote the development of metastases (Welch et al. 1990; Yin et al. 1999) . These effects become manifest in tumor cells that retain TGF␤ receptors but have lost the capacity to respond to TGF␤ with growth arrest. Such a state of altered TGF␤ responsiveness is observed in Ras-transformed cells. These cells typically exhibit a limited growth inhibitory response to TGF␤ (Schwarz et al. 1988; Houck et al. 1989; Valverius et al. 1989; Longstreet et al. 1992; Filmus and Kerbel 1993) but may respond to TGF␤ with invasive activity (Oft et al. 1996) and metastatic behavior (Oft et al. 1998; Yin et al. 1999) .
TGF␤ exerts growth inhibitory and transcriptional responses through Smad2 and the highly related protein Smad3, which are direct TGF␤ receptor substrates, whereas Smad1 is a substrate and mediator of bone morphogenetic protein (BMP) receptors (Heldin et al. 1997; Massagué 1998) . Receptor-mediated phosphorylation of these Smads, which occurs at serine residues in the carboxy-terminal SSXS sequence (Macias-Silva et al. 1996; Kretzschmar et al. 1997b) , induces their association with the shared partner Smad4 followed by translocation into the nucleus in which these complexes activate transcription of specific genes (Heldin et al. 1997; Massagué 1998) . Smad proteins contain a conserved amino-termi-nal domain that binds DNA , and a conserved carboxy-terminal domain that binds receptors, partner Smads, and transcription coactivators (Shi et al. 1997; X. Chen et al. 1998 ). These two domains are separated by a more divergent linker region.
How oncogenic Ras counteracts the growth inhibitory effects of TGF␤ has remained unknown. Although oncogenic Ras can prevent the antimitogenic effects of TGF␤, TGF␤ potently overcomes the mitogenic effects of Rasactivating factors such as EGF in epithelial cells (Massagué 1990; Roberts and Sporn 1993; Alexandrow and Moses 1995) . To investigate the molecular basis for these interactions, we focused on Smad2 and Smad3 as possible targets of inhibition by Ras. Here we show that Ras activation by oncogenic mutations or, to a lesser extent, by EGF receptor signals, inhibits the TGF␤-induced nuclear accumulation of Smad2 and Smad3. These effects are mediated by phosphorylation of specific sites in Smad2 and Smad3, and we demonstrate that these sites are distinct from the TGF␤ receptor phosphorylation sites. We present evidence that this mechanism mediates the silencing of TGF␤ antimitogenic responses in Ras-transformed cells, whereas in normal cells this mechanism serves to adjust the level of TGF␤/Smad signaling according to the level of Ras activity in the cell. These results reconcile a diverse body of observations on the interaction between the TGF␤ and Ras pathways, and provide insights into the subversion of TGF␤ signaling by oncogenic Ras mutations in cancer.
Results

Ras inhibition of Smad-dependent TGF␤ responses
We investigated Ras as an antagonist of TGF␤ signaling using a well-characterized mouse mammary epithelial cell system (Oft et al. 1996) . The parental cell line EpH4 is nontumorigenic and responds to TGF␤ with growth inhibition, whereas its v-Ha-Ras-transformed derivative, EpRas, responds with a transition into a fibroblastoid phenotype that is not growth inhibited and is highly invasive in vivo (Oft et al. 1996) . We investigated whether loss of growth inhibitory responses to TGF␤ in EpRas cells might be related to Ras inhibition of Smad transcriptional functions. One of the best understood Smad target promoters is that of the Mix.2 gene from Xenopus laevis (Y. Chen et al. 1996; X. Chen et al. 1997; Liu et al. 1997) . On translocation into the nucleus, receptor-activated Smad2 or Smad3 associate with the DNA-binding protein FAST1 to form a transcriptional complex on the activin/TGF␤ response element (ARE) of the Mix.2 promoter (Y. Chen et al. 1996; X. Chen et al. 1997; Liu et al. 1997) . Strong (up to 14-fold) activation of an ARE reporter construct (A3-Luc) by TGF␤ was achieved in EpH4 cells cotransfected with FAST1 (data not shown) or its mammalian homolog FAST2 (Labbé et al. 1998; Zhou et al. 1998; Liu et al. 1999) (Fig. 1A) . In contrast, FAST2-transfected EpRas cells showed only a weak (twofold) activation of A3-Luc by TGF␤, suggesting that Smad signaling was impaired (Fig. 1A) .
EpRas cells may have accumulated Ras-independent defects in TGF␤ signaling over time. Therefore, we verified the ability of oncogenic Ras to inhibit A3-Luc activation by transiently transfecting a H-Ras V12 oncogene into Mv1Lu mink lung epithelial cells. This cell line is highly sensitive to growth inhibition and A3-Luc activation by TGF␤. The TGF␤-induced activation of A3-Luc in these cells was strongly inhibited by cotransfection of H-Ras V12 (Fig. 1B) . Transient transfection of H-Ras V12 also inhibited the antiproliferative response to TGF␤, as determined with an E2F-1 reporter construct whose activity is a measure of G 1 progression (Lukas et al. 1997; Fig. 1C) . Thus, in a stably transfected mammary epithelial cell line and in a transiently transfected lung epithelial cell line, the presence of oncogenic Ras caused not only a loss of antiproliferative responses to TGF␤ but also of Smad-dependent transcriptional responses. . G 1 progression activity was determined with an E2F reporter construct driving luciferase expression. In all cases, data are the average of triplicates ±S.D.
Inhibition of Smad2/Smad3 nuclear accumulation by oncogenic Ras
Translocation of Smad2 and Smad3 into the nucleus on receptor-mediated phosphorylation is a central event in TGF␤ signal transduction (Heldin et al. 1997; Massagué 1998) . Growth factors that signal via Ras, such as EGF, can inhibit the BMP-induced nuclear accumulation of Smad1 by inducing its phosphorylation at four PXSP Erk sites (Kretzschmar et al. 1997a ). These four sites are not conserved in Smad2 or Smad3. Nevertheless, we decided to investigate whether oncogenic Ras might inhibit nuclear accumulation of endogenous Smads in response to TGF␤. Rabbit polyclonal antibodies were raised against the recombinant linker region of Smad2 and tested by Western immunoblotting on transfected COS cells expressing different Flag-tagged Smads. These antibodies specifically recognized Smad2, and to a lesser extent Smad3, but not Smad1 or Smad4 ( Fig. 2A) . This cross-reactivity profile is consistent with the high level of amino acid sequence similarity of the Smad2 and Smad3 linker region and the extensive divergence of this region in the other Smads (Zhang et al. 1996) . Immunoblot assays of untransfected EpH4, EpRas, and Mv1Lu cells with these antibodies demonstrated the presence of Smad2 and lower levels of Smad3 in each cell line (Fig.  2B ). Using antibodies that specifically recognize the TGF␤ receptor-phosphorylated Smad2, we determined that endogenous Smad2 in both EpH4 and EpRas cells is phosphorylated in response to TGF␤ (Fig. 2C) . Thus, Ras transformation did not interfere with TGF␤ receptor-mediated phosphorylation of Smad2 in EpRas cells.
We determined the immunofluorescence pattern of endogenous proteins in EpH4 and EpRas using antiSmad2/Smad3 antibodies (Fig. 2D) . In the absence of TGF␤, both cell lines showed anti-Smad2/Smad3 staining throughout the cell. On TGF␤ addition, >95% of the EpH4 cells showed an accumulation of all the Smad2/ Smad3 immunostaining in the nucleus (Fig. 2D ). This nuclear accumulation was rapid and lasted for at least 3 hr (Fig. 2E ). Compared to EpH4 cells, EpRas cells responded to TGF␤ with a limited accumulation of Smad2/Smad3 in the nucleus. Furthermore, this accumulation was slow and only partial, as most cells with predominant nuclear staining still showed an extensive staining in the cytoplasm (Fig. 2D,E) . We also examined the pattern of Smad2/Smad3 nuclear accumulation in five human colon carcinoma cell lines, three of which contain oncogenic K-Ras mutations (Table 1 ). Nuclear accumulation of Smad2/Smad3 in response to an intermediate (10 pM) TGF␤ concentration was poor or absent in these three cell lines but extensive in the two cell lines containing wild-type ras alleles.
To directly test whether oncogenic Ras can interfere with nuclear accumulation of endogenous Smad2 and Smad3, we transiently transfected Mv1Lu cells with HRas fected cells in the dish. Up to 95% of the control vector transfected (GFP positive) cells showed nuclear accumulation of endogenous Smad2/Smad3 in response to TGF␤ (Fig. 3A) . In contrast, only a small proportion (16%) of the H-Ras V12 transfected cells showed nuclear accumulation of Smad2/Smad3 (Fig. 3A) . A similar effect was observed in cells expressing a constitutively active form of Mek1 (Fig. 3B) , which is an activator of Erk MAP kinases downstream of Ras (Davis 1993 ). GFP-negative cells, which served as internal controls in these assays, had extensive Smad2/Smad3 staining in the nucleus in the presence of TGF␤ (Fig. 3) . A similar inhibition of Smad2/Smad3 nuclear accumulation by transfection of a H-Ras V12 vector was observed in the two tumor cell lines containing wild-type ras alleles (Table 1) .
Ras induces phosphorylation of Smad2 and Smad3 in the linker region
Next, we investigated whether Ras inhibition of Smad nuclear accumulation involves Smad phosphorylation. Activated Ras propagates signals through the activation of protein kinases including the MAP kinases p44 Erk1 and p42
Erk2 (Davis 1993) . The levels of these two proteins were similar in EpH4 and EpRas cells, as determined by Western immunoblotting with anti-Erk antibodies (Fig. 4A, bottom) . However, the level of Erk activity was higher in EpRas cells than in EpH4 cells, as determined by measuring the kinase activity of Erk immunoprecipitates (Fig. 4A, top) . This result was consistent with the presence of hyperactive Ras in EpRas cells. Interestingly, immunoprecipitation of endogenous Smad2 and Smad3 from 32 P-labeled cells showed that the level of phosphorylation of these proteins was higher in EpRas cells than in EpH4 cells (Fig. 4B) . Elution of the 32 P-labeled EpRas Smad band from these gels followed by digestion with trypsin yielded labeled products of no less than 13 kD, whereas digestion with ␣-chymotrypsin yielded mostly products of <5 kD (data not shown). On the basis of the predicted proteolytic sites of Smad2 and Smad3 (Zhang et al. 1996) , the observed digestion pattern suggests that most of the phosphorylation resides in the linker region of these proteins.
Cell stimulation with EGF has been shown to inhibit the BMP-induced nuclear accumulation of Smad1, and this effect requires the phosphorylation of four Erk kinase sites (PXS/TP) in the linker region of Smad1 (Kretzschmar et al. 1997a ). Smad2 has only one Erk site in the linker region (Thr-220) and Smad3 has two (Thr-178, Ser-212) (Fig. 5A) . However, the Smad2 linker region has three Ser-Pro sequences and Smad3 has two . These sequences can serve as phosphorylation sites for proline-directed protein kinases including Erk (Davis 1993) . Therefore, we asked whether Ras pathway activation causes phosphorylation of these sites. Smad2 and Smad3 constructs were generated that encoded serine-to-alanine or threonine-to-valine mutations at all these sites (Erk/Pro-directed kinase site mutant constructs, EPSM). Wild-type or EPSM Smad constructs containing a amino-terminal Flag epitope were transiently transfected either alone or together with H-Ras V12 or activated Mek1 vectors into Mv1Lu/R1B-L17 cells. Cell labeling with 32 P followed by anti-Flag immunoprecipitation showed that Smad2 and Smad3 were phosphorylated under normal culture conditions, and the phosphorylation level of these proteins was increased by transfection of H-Ras V12 or activated Mek1 vectors (Fig. 5B,C) . Treatment of the Rastransfected cells with the inhibitor of Mek1 activation PD98059 (Alessi et al. 1995) or the inhibitor of phosphatidylinositol 3-kinase, Wortmannin (Ui et al. 1995) , partially inhibited Smad2 and Smad3 phosphorylation, implicating these kinases in the Ras-induced phosphorylation (Fig. 5B,C) . The results suggest that the basal activity of the Ras pathway and, to a larger extent, the hyperactivation of this pathway by H-Ras V12 or activated Mek1, cause the phosphorylation of Smad2 and Smad3.
Erk kinase phosphorylation sites in the linker region
Compared with the transfected Smad2 and Smad3, their corresponding EPSM constructs showed very low levels of phosphorylation, and these levels were not increased by H-Ras V12 (Fig. 5B,C) . To verify that Erk kinases can directly phosphorylate Smad2 and Smad3 at the identified sites, we performed in vitro kinase assays using re- . Cells were incubated with 10 pM TGF␤ for 30 min and subjected to anti-Smad2/3 immunofluorescence. The percentage of cells with predominant nuclear staining in the total nontransfected population or in the transfected (GFP positive) population is shown. (N.T.) Not tested.
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Cold Spring Harbor Laboratory Press on January 25, 2018 -Published by genesdev.cshlp.org Downloaded from combinant forms of these proteins. Recombinant, activated Erk2 phosphorylated Smad2 and Smad3 to a much greater extent than it phosphorylated Smad2-EPSM or Smad3-EPSM (Fig. 5D ). We also tested Smad2 and Smad3 constructs containing hydroxyl residue mutations either in the PXS/TP sites or in the other SP sites. Each of these four mutants showed a partial loss of phosphorylation compared with the EPSM constructs, both in Ras transfected cells and in in vitro Erk2 phosphorylation assays (data not shown).
We also tested Smad2(3SA) and Smad3(3SA) constructs that contain alanine mutations in the three serines of the carboxy-terminal sequence SSXS (Kretzschmar et al. 1997b ). These serines serve as TGF␤ receptor phosphorylation sites and are required for Smad translocation into the nucleus (Macias-Silva et al. 1996) . H-Ras V12 transfection of Mv1Lu/R1B-L17 cells induced phosphorylation of both 3SA constructs (Fig. 5E) , arguing that the TGF␤-receptor phosphorylation sites are not required for Ras-induced phosphorylation. Collectively, these results suggest that oncogenic Ras, acting through Mek1 and Erk kinases, induces the phosphorylation of Smad2 and Smad3 at a cluster of Ser/Thr-Pro sites in the linker region.
Effects of EGF on Smad2 and Smad3 phosphorylation and nuclear accumulation
As EGF is a physiological activator of the Ras pathway (Vojtek and Der 1998), we investigated its effects on Smad2 and Smad3 phosphorylation and nuclear accumulation. EGF was reported to cause an increase in the phosphorylation levels of an endogenous Smad2 in Mv1Lu cells (deCaesteker et al. 1998 ). In agreement with this result, we observed that EGF induces phosphorylation of exogenous Smad2 and Smad3 in transfected Mv1Lu/R1B-L17 cells (Fig. 6A) . However, Ras activation in response to EGF is thought to be less extensive than Ras activation by oncogenic mutations. The increase in . The EGF-induced phosphorylation requires the same cluster of sites in the linker region, as EGF did not elevate the phosphorylation of Smad2-EPSM or Smad3-EPSM, which lack these sites (Fig. 6A) . Like H-Ras V12 , EGF elevated the phosphorylation of Smad2(3SA) and Smad3(3SA), which lack the TGF␤ receptor phosphorylation sites (Fig. 5E) .
Next, we examined the effect of EGF on TGF␤-induced nuclear accumulation of endogenous Smads. EGF added alone had no discernible effect on the staining pattern of endogenous Smad2/Smad3 in Mv1Lu cells. Whether added alone or together with EGF, TGF␤ induced an accumulation of Smad2/Smad3 in the nucleus (Fig. 6B) . However, EGF clearly limited the extent of this accumulation. When TGF␤ was added alone, almost all cells in the population showed an intense nuclear accumulation of Smad2/Smad3 with very little immunostaining left in the cytoplasm. In the presence of EGF, the nuclear accumulation of Smad2/Smad3 was less extensive, and a substantial level of Smad2/Smad3 staining remained in the cytoplasm in most cells (Fig. 6B) . EGF was more effective at inhibiting the effect of 10 pM TGF␤ (Fig. 6B) than that of 100 pM TGF␤ (data not shown), suggesting that the extent of Smad2/Smad3 nuclear accumulation depends on the relative strength of countervailing TGF␤ and EGF signals.
Linker phosphorylation inhibits nuclear accumulation
These results showed a correlation between a Ras-induced phosphorylation of a cluster of MAP kinase sites in the linker region of Smad2/Smad3 and an inhibition of TGF␤-induced nuclear accumulation of these Smads. To directly test whether phosphorylation of these sites is required for inhibition of nuclear accumulation, we cotransfected vectors encoding activated Mek1 and either Flag-tagged Smad3 or Smad3-EPSM constructs into Mv1Lu cells. Similar to its effect on the nuclear accumulation of endogenous Smad2/Smad3 (see Fig. 3 ), the activated Mek1 inhibited the TGF␤-induced nuclear accumulation of Flag-Smad3 (Fig. 7A,B) . However, FlagSmad3-EPSM was resistant to this inhibitory effect, as it accumulated in the nucleus in response to TGF␤ even in the presence of activated Mek1 (Fig. 7A,B) . Inhibition of Smad3 nuclear accumulation by activated Mek1 therefore requires the linker region MAP kinase phosphorylation sites.
Ras-resistant Smad3 rescues TGF␤ antimitogenic and transcriptional responses
Finally, we used the Smad3-EPSM construct to investigate whether the TGF␤ responses lost in EpRas cells could be restored by a Ras-resistant Smad3 mutant. TGF␤ addition inhibited the activity of the E2F-1-lucif- 
(E) Effects of H-Ras
V12 cotransfection or EGF addition (18 nM, 30 min) on the phosphorylation of Flag-tagged Smad constructs containing Ser → Ala mutation in the carboxy-terminal SSXS receptor phosphorylation sites. Other assay conditions and controls were as described above.
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Cold Spring Harbor Laboratory Press on January 25, 2018 -Published by genesdev.cshlp.org Downloaded from erase reporter assay in EpH4 cells but not in EpRas cells (Fig. 8) . This result is consistent with the previously described loss of antiproliferative responses in EpRas cells (Oft et al. 1997) . Transfection of either wild-type Smad3 or Smad3-EPSM into EpH4 cells did not significantly enhance this antimitogenic effect of TGF␤ (Fig. 8A) . However, Smad3-EPSM restored the ability of TGF␤ to inhibit the E2F-1 reporter in EpRas cells, whereas wildtype Smad3 had only a small effect (Fig. 8A) .
We also tested the effect of Smad3 or Smad3-EPSM transfection on the activation of the A3-Luc reporter (Fig. 8B) . A3-Luc activation by TGF␤ in EpH4 cells was only slightly increased by transfection of Smad3 or Smad3-EPSM vectors. However, transfection of Smad3-EPSM into EpRas cells strongly enhanced the otherwise limited response of A3-Luc to TGF␤, whereas transfection of the wild-type Smad3 had only a small effect (Fig.  8B) . EpRas cells transfected with Smad3-EPSM vector had a high level of basal luciferase activity that may be due to spontaneous accumulation of the overexpressed product in the nucleus. These results further suggest that Smad phosphorylation by Ras-activated MAP kinases is responsible for the decreased responsiveness of Ras-transformed cells to TGF␤.
Discussion
We have investigated the mechanism of inhibition of TGF␤ signaling by the Ras pathway in epithelial cells. Our results suggest that Ras activation induces the phosphorylation of MAP kinase sites in the linker region of Smad2 and Smad3, inhibiting the nuclear accumulation of the Smads and their ability to mediate TGF␤ antiproliferative responses and other effects. In normal epithelial cells, this mechanism may function to adjust the level of Smad signaling according to the level of Ras activity. However, in the case of Ras hyperactivation by oncogenic mutations, a common event in several human cancers, the same mechanism may cause the loss of growth inhibition by TGF␤.
Repression of TGF␤/Smad signaling by the Ras pathway
Numerous reports have described a correlation between Ras transformation and deficient TGF␤ responsiveness, particularly with regards to TGF␤ antimitogenic responses. Ras transformation of lung, intestinal, liver, or mammary epithelial cells confers resistance to growth inhibition by TGF␤ (Schwarz et al. 1988; Houck et al. 1989; Valverius et al. 1989; Longstreet et al. 1992; Filmus and Kerbel 1993) . Microinjection of oncogenic H-Ras protein into TGF␤-arrested mink lung epithelial cells overcomes TGF␤ growth inhibition and allows cell-cycle progression into S phase (Howe et al. 1993) . Here, we describe a mechanism by which oncogenic Ras can induce such losses of TGF␤ responsiveness.
Our results show that oncogenic Ras inhibits the TGF␤ signal transduction pathway at the level of Smad. As a readout of Smad transcriptional activity we used the A3-Luc reporter because activation of the enhancer element ARE that drives gene expression in A3-Luc depends on the direct binding of a TGF␤-induced Smad (a TGF␤-induced Smad complex) (Chen et al. 1997; Liu et al. 1997) . Oncogenic Ras inhibits the A3-Luc transcriptional response to TGF␤, both in mammary epithelial cells and lung epithelial cells. H-Ras V12 decreases the amplitude of the A3-Luc response by as much as 90%. This is accompanied by a similar inhibition of the TGF␤ antimitogenic response.
Ras signaling was shown previously to induce the phosphorylation of the BMP mediator Smad1 at four Erk consensus sites in the linker domain (Kretzschmar et al. 1997a) . Phosphorylation of these four sites inhibits Smad1 accumulation in the nucleus without interfering with BMP-induced phosphorylation of Smad1. Many other serine residues present in the Smad1 linker region are not required for this effect (Kretzschmar et al. 1997a) . A similar mechanism of regulation was not predicted for Smad2 or Smad3. These proteins are divergent from Smad1 in the linker region and have only one or two consensus Erk sites. However, our evidence suggests that clusters of four Ser/Thr-Pro sites including these Erk sites in the linker region of Smad2 and Smad3 are functionally equivalent to the four Erk sites of Smad1.
The following lines of evidence support the conclusion that Ras-induced phosphorylation of these sites prevents accumulation of Smad2 and Smad3 in the nucleus and inhibits TGF␤ signaling. First, expression of oncogenic Ras elevates the phosphorylation of endogenous as well as exogenous Smad2 and Smad3. Second, Ras-induced phosphorylation of Smad2 and Smad3 is mimicked by expression of an activated Mek1 construct and is inhibited by addition of a specific Mek1 inhibitor. Third, these Ras-and Mek1-induced phosphorylations are prevented by mutation of the four Ser/Thr-Pro sites in the linker region of Smad2 and Smad3. These mutations also inhibit the phosphorylation of Smad2 and Smad3 by Erk2 in vitro. In contrast, mutation of the carboxy-terminal serines that serve as TGF␤ receptor phosphorylation sites does not inhibit Ras-induced phosphorylation of Smad2 or Smad3. Fourth, expression of oncogenic Ras or constitutively active Mek1 inhibit the TGF␤-induced accumulation of Smad2 and Smad3 in the nucleus. Fifth, Mek1 does not inhibit the TGF␤-induced accumulation of a mutant Smad3 lacking the four Ras-dependent phosphorylation sites. Finally, expression of this Ras-resistant Smad3 mutant restores growth inhibitory and transcriptional responses to TGF␤ in Ras-transformed cells.
Smad2 and Smad3 integrate antagonistic TGF␤ and Ras signals
What is the role of this inhibitory mechanism in epithelial cells that contain a normal Ras pathway? We have approached this question by studying the effect of EGF, a physiological activator of this pathway (Vojtek and Der 
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Cold Spring Harbor Laboratory Press on January 25, 2018 -Published by genesdev.cshlp.org Downloaded from 1998). It should be noted that TGF␤ is a potent inhibitor of the mitogenic response to EGF in Mv1Lu cells and other nontransformed epithelial cells (Like and Massagué 1986; Massagué 1990; Alexandrow and Moses 1995) . TGF␤ antagonizes these signals by inhibiting G 1 cyclin-dependent kinases (Koff et al. 1993; Hannon and Beach 1994; Polyak et al. 1994; Iavarone and Massagué 1997; Reynisdó ttir and Massagué 1997) . Therefore, EGF may not be expected to cause an extensive inhibition of TGF␤ signaling, and our results agree with this. Like oncogenic Ras, EGF elevates the phosphorylation of Smad2 and Smad3, and this requires the four Ser/ThrPro sites in the linker region but not the carboxy-terminal receptor phosphorylation sites. However, EGF, which is weaker than oncogenic mutations at activating Ras, only tones down the nuclear accumulation of Smad2 and Smad3. On balance, TGF␤ prevails over EGF in the regulation of Smad2/Smad3 nuclear accumulation. Thus, physiological signals and oncogenic mutations that activate Ras induce phosphorylation of the same inhibitory sites in Smad2 and Smad3, but with different intensities and different outcomes. Physiological activators such as EGF may use this mechanism to adjust the ability of Smad2 and Smad3 to convey TGF␤ signals, whereas oncogenic Ras mutations may use it to disrupt TGF␤ signaling.
Adjusting the ability of Smad2 and Smad3 to convey TGF␤ signals may be important in processes that are cooperatively stimulated by TGF␤ and Ras signals. Activin-like TGF␤ family members cooperate with Ras signals in the induction of mesoderm in Xenopus (Whitman and Melton 1992) . During endoderm formation in Drosophila, Ras signals and the TGF␤ family member Dpp synergize in the induction of a common target gene, Ubx, by activating separate sites in the Ubx promoter (Szü ts et al. 1998) . TGF␤ and EGF acting together allow the proliferation of fibroblasts under anchorage-deficient conditions (Roberts and Sporn 1990) . TGF␤ may allow the mitogenic stimulation of anchorage-deprived fibroblasts by inducing formation of extracellular matrix and cell adhesion to this matrix (Ignotz and Massagué 1986, 1987) . Integrin-mediated adhesion to an extracellular matrix is required for effective mitogenic stimulation (Assoian and Zhu 1997) .
EGF and hepatocyte growth factor (HGF) have been shown to activate the TGF␤ reporter plasmid p3TP-Lux (Cá rcamo et al. 1995; de Caestecker et al. 1998) . On the basis of these and related observations, it has been proposed that EGF and HGF may signal through Smad2 (de Caestecker et al. 1998) . Compared with TGF␤, however, these factors induce minimal or no accumulation of Smad2 in the nucleus (de Caestecker et al. 1998; present results) . It should be noted that the p3TP-Lux promoter contains three AP-1 sites (Cá rcamo et al. 1995) , and EGF can activate AP-1 directly through the Ras/MAPK pathway (Hunter and Karin 1992; Davis 1993) . Other AP-1 activators such as phorbol esters also activate the 3TP-Lux construct (Cá rcamo et al. 1995) . Ras signaling slightly elevates the transcriptional activity of a GAL4-Smad2 fusion construct (de Caestecker et al. 1998 ), but Ras signaling has a general effect on transcription (Abdellatif et al. 1994 ) and can stimulate general transcriptional coactivators (Xu et al. 1998) . Our results do not support the notion that EGF specifically signals through Smad2.
Implications for cancer
One physiological function of TGF␤ is to constrain the proliferation of epithelial, endothelial, and hematopoietic cells, thus contributing to the maintenance of homeostasis in these tissues (Massagué 1990; Roberts and Sporn 1993; Alexandrow and Moses 1995) . This function of TGF␤ is often lost in cancer as a result of mutations that directly inactivate components of the growthinhibitory TGF␤/Smad signaling pathway including T␤R-II, Smad2, and Smad4 (Markowitz et al. 1995; Eppert et al. 1996; Hahn et al. 1996; Heldin et al. 1997; T. Chen et al. 1998; Goggins et al. 1998; Massagué 1998; Grady et al. 1999 ). However, many tumor cells without known mutations in these components are refractory to growth inhibition by TGF␤. Understanding the mechanisms by which certain tumor cells selectively lose growth-inhibitory responses to TGF␤ is therefore important for a better understanding of oncogenic processes.
We have investigated this problem in Ras-transformed mammary and lung epithelial cells. Our results suggest that hyperactive Ras can interfere with the TGF␤/Smad signaling pathway by inhibiting nuclear accumulation of Smad2/Smad3. This mechanism may be operative in tumors that harbor a hyperactive Ras pathway. A substantial proportion of colon carcinomas and pancreatic carcinomas contain oncogenic Ras mutations (Fearon and Vogelstein 1990; Kern 1998) , whereas breast carcinomas often contain HER2 and EGFR receptor tyrosine kinase amplifications (Clark and Der 1995) . The colon carcinoma cell lines of known Ras status that we have screened to date show a correlation between the presence of oncogenic Ras mutations and a deficient nuclear accumulation of Smad2/Smad3. Tumors that contain inactivating mutations in T␤RII, Smad2, or Smad4 may suffer a more complete loss of TGF␤ signaling than tumors containing Ras mutations. However, Ras mutations and mutations in TGF␤ pathway components diminish TGF␤ signaling with different outcomes. Ras transformation not only diminishes growth inhibition by TGF␤, but it subverts this pathway into stimulating epithelial-mesenchymal transdifferentiation, invasion, and metastasis (Welch et al. 1990; Caulin et al. 1995; Oft et al. 1996 Oft et al. , 1998 Sehgal et al. 1996; Farina et al. 1998; Yin et al. 1999 ). The inhibitory mechanism described here may allow the emergence of these tumorigenic responses through the residual activity of Smads remaining in the tumor cells or through as yet unknown Smadindependent pathways.
Materials and methods
Cell lines
Parental Mv1Lu cells were obtained from the American Type Culture Collection. Mv1Lu/R1B-L17 is a derivative cell line defective in the TGF␤ type I receptor (T␤RI) that has a high transfection efficiency and responds to TGF␤ on transfection of T␤R-I (Wrana et al. 1994 ). EpH4 and EpRas were a generous gift of E. Reichmann (ISREC, Lausanne, Switzerland). Colon cancer cell lines were provided by N. Rosen (Memorial Sloan-Kettering Cancer Center, New York, NY).
Transfections and metabolic labeling
Most procedures were essentially carried out as described (Kretzschmar et al. 1997b ). In brief, Mv1Lu/R1B-L17 mink lung epithelial cells were transiently transfected with Flag-tagged Smad2 or Smad3 constructs and H-Ras V12 or caMek1 vectors as indicated. Smad constructs and H-Ras V12 were in pCMV5 or pCS2, caMek1 was in pMCL. Mutant Smad constructs were obtained by standard in vitro mutagenesis procedures and were confirmed by sequencing. Three days post-transfection, cells were metabolically labeled for 3 hr with 32 P and lysed. Where indicated, cells were treated with EGF (18 nM; R&D systems) for the indicated time, or with the Mek1 inhibitor PD98059 (100 µM; New England Biolabs), or the PI3-kinase inhibitor wortmannin (0.1 µM; Calbiochem) for 1.5 hr prior to cell lysis. After cell lysis, Flag-Smad2 and Flag-Smad3 were precipitated with antiFlag antibody, resolved by SDS-PAGE, and visualized by autoradiography. Parallel cultures were treated equivalently, lysed, and subjected to Western immunoblotting with anti-Flag antibody and chemiluminescence (ECL, Amersham).
Reporter assays
Luciferase assays were essentially carried out as described (Kretzschmar et al. 1997a ). The A3-Luc reporter construct was generated by subcloning the region comprising the three AREs and the core promoter from the previously described A3-CAT construct (Huang et al. 1995) into the pGL2-Basic luciferase vector (Promega). For A3-Luc assays, cells were transiently cotransfected with FAST-2 and A3-Luc vectors, serum-starved for 6 hr, treated with TGF␤ at the indicated concentrations, and assayed for luciferase activity 18 hr after factor addition. For E2F-luciferase assays, cells were transiently transfected with empty vector or vector encoding wild-type Smad3 or Smad3-EPSM, as indicated, and the E2F-luciferase reporter construct 6×E2F-Luc (Lukas et al. 1997) as specified. Assays were carried out equivalently except that cells were not serum starved. EpH4 and EpRas cells were grown as described previously (Oft et al. 1996) .
Antibodies
Anti-Smad2/Smad3 antibodies were raised in rabbits by immunization with the recombinant linker region of human Smad2 (amino acids 183-273), which is almost identical across species and highly homologous to the corresponding region in Smad3. These antibodies, referred to as anti-Smad2/Smad3, were affinity purified with immobilized Smad2 prior to use. Rabbit polyclonal antibodies raised against a peptide corresponding to amino acids 457-467 of Smad2, which included phosphorylated serine residues at positions 465 and 467 (Upstate Biotechnology, Lake Placid, NY) was used for Western immunoblotting of carboxyl terminus phosphorylated Smad2. Rabbit polyclonal antiErk antibodies used for Western immunoblotting (Upstate Biotechnology) and immunoprecipitation (Santa Cruz) recognize both Erk1 and Erk2. Monoclonal anti-Flag antibody (M2) was from Kodak Scientific.
Immunofluorescence assays
Vector, H-Ras V12 , caMek1, GFP, or Flag-Smad3 constructs were transiently transfected 48 hr prior to factor treatment. Cells were treated with TGF␤ and/or EGF as specified and processed for immunofluorescence by a triple sandwich method (Harlow and Lane 1988) . Endogenous Smad proteins were visualized with affinity-purified anti-Smad2/Smad3 antibodies, biotinconjugated anti-rabbit immunoglobulin and either FITC-or rhodamine-conjugated streptavidin (Jackson ImmunoResearch, West Grove, PA). Exogenous Flag-tagged Smad proteins were visualized with the triple sandwich method by use of M2 antiFlag monoclonal antibodies (Kodak) as primary antibodies. All slides were counterstained with DAPI to visualize cell nuclei (data not shown). In all cases, at least 100 stained cells were scored.
Kinase assays
Smad constructs were subcloned into a pET expression vector (Novagen) encoding an amino-terminal hexahistidine tag. Bacterial expression and purification of recombinant proteins were carried out as described (Kretzschmar et al. 1997b) . Equivalent amounts of recombinant Smad3 proteins, as quantified by Coomassie staining and protein concentration assays, were incubated with recombinant, activated Erk2 MAP kinase (New England Biolabs) in the presence of [␥-32 P]ATP at 28-30°C for 20 min. Reactions were stopped by addition of SDS loading buffer and proteins resolved by SDS-PAGE.
Phosphopeptide analysis
EpRas cells were metabolically labeled for 3 hr with 32 P and lysed. Endogenous Smad2/Smad3 was immunoprecipitated with affinity-purified anti-Smad2/Smad3 and separated by SDS-PAGE. Endogenous Smad2/Smad3 was visualized by autoradiography and then electroeluted from the gel. The eluted protein was concentrated and aliquots incubated with trypsin or ␣-chymotrypsin (both from Worthington, Lakewood, NJ). Resulting phosphopeptides were resolved by SDS-PAGE and visualized by autoradiography.
